KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Resmed (RMD) Operating Expenses (2016 - 2025)

Resmed (RMD) has disclosed Operating Expenses for 17 consecutive years, with $387.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 15.88% year-over-year to $387.1 million, compared with a TTM value of $1.5 billion through Dec 2025, up 11.44%, and an annual FY2025 reading of $1.4 billion, up 2.56% over the prior year.
  • Operating Expenses was $387.1 million for Q4 2025 at Resmed, up from $374.3 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $387.1 million in Q4 2025 and bottomed at $223.8 million in Q1 2021.
  • Average Operating Expenses over 5 years is $309.4 million, with a median of $317.6 million recorded in 2023.
  • The sharpest move saw Operating Expenses grew 28.08% in 2023, then dropped 10.17% in 2024.
  • Year by year, Operating Expenses stood at $255.6 million in 2021, then grew by 17.18% to $299.5 million in 2022, then increased by 24.14% to $371.8 million in 2023, then dropped by 10.17% to $334.0 million in 2024, then increased by 15.88% to $387.1 million in 2025.
  • Business Quant data shows Operating Expenses for RMD at $387.1 million in Q4 2025, $374.3 million in Q3 2025, and $365.5 million in Q2 2025.